TRBV7-9: A Potential Drug Target for Cancer (G28589)

Target Name: TRBV7-9

NCBI ID: G28589

Other Name(s): TCRB | TRBV79 | TCRBV6S4A1 | TCRBV7S9 | T cell receptor beta variable 7-9

TRBV7-9: A Potential Drug Target for Cancer

TRBV7-9 (Tumor-associated runtime binding protein 7-9) is a protein that is expressed in various tissues of the body, including the brain, lung, heart, liver, and kidney. It is a member of the TRB family, which is known for its role in cell-cell and cell-tissue interactions. TRBV7-9 has been identified as a potential drug target or biomarker for various diseases, including cancer.

The TRBV7-9 protein is involved in several cellular processes that are important for normal cell function and development. One of its functions is to regulate cell adhesion, which is the process by which cells stick together to form tissues and organs. In cancer, abnormal cell adhesion can contribute to tumor progression and the development of invasive and metastatic tumors.

Another function of TRBV7-9 is to regulate cell signaling pathways, which are the processes by which cells communicate with one another and with the cell membrane. These signaling pathways are important for cell growth, differentiation, and survival, and are often disrupted in cancer. TRBV7-9 has been shown to play a role in regulating several signaling pathways that are important for cancer development, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

In addition to its role in cell signaling pathways, TRBV7-9 is also involved in the regulation of cell cycle progression. The cell cycle is the process by which cells grow, divide, and replicate their genetic material. Disruptions in cell cycle progression, such as those that occur in cancer, can contribute to tumor growth and the development of invasive and metastatic tumors. TRBV7-9 has been shown to play a role in regulating the cell cycle, including the G1/S transition, which is the stage of the cell cycle where cells prepare for cell division.

TRBV7-9 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels form in the body. Angiogenesis is important for the development of tumors, and is often disrupted in cancer. TRBV7-9 has been shown to play a role in regulating angiogenesis, including the production of new blood vessels and the formation of blood-brain barriers.

In conclusion, TRBV7-9 is a protein that is involved in several cellular processes that are important for normal cell function and development. Its role in cell adhesion, signaling pathways, cell cycle progression, and angiogenesis makes it a potential drug target or biomarker for various diseases, including cancer. Further research is needed to fully understand the role of TRBV7-9 in cancer development and to develop effective therapies that target this protein.

Protein Name: T Cell Receptor Beta Variable 7-9

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

More Common Targets